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Background: Infrapatellar fat pad (IFP) has recently emerged as a potential source of inflammation in knee
arthropathies. It has been proposed to be one source of adipocytokines, fatty acids (FA), and FA-derived lipid mediators
that could contribute to the pathophysiological processes in the knee joint. Alterations in synovial fluid (SF) lipid
composition have been linked to both osteoarthritis (OA) and rheumatoid arthritis (RA). The aim of the present study
was to compare the FA signatures in the IFP and SF of RA and OA patients.
Methods: Pairs of IFP and SF samples were collected from the same knees of RA (n = 10) and OA patients (n = 10)
undergoing total joint replacement surgery. Control SF samples (n = 6) were harvested during diagnostic or therapeutic
arthroscopic knee surgery unrelated to RA or OA. The FA composition in the total lipids of IFP and SF was determined
by gas chromatography with flame ionization and mass spectrometric detection.
Results: Arthropathies resulted in a significant reduction in the SF proportions of n-6 polyunsaturated FA (PUFA), more
pronouncedly in OA than in RA. OA was also characterized with reduced percentages of 22:6n-3 and lower product/
precursor ratios of n-3 PUFA. The proportions of total monounsaturated FA increased in both RA and OA SF. Regarding
IFP, RA patients had lower proportions of 20:4n-6, total n-6 PUFA, and 22:6n-3, as well as lower product/precursor ratios
of n-3 PUFA compared to OA patients. The average chain length of SF FA decreased in both diagnoses and the double
bond index in OA.
Conclusions: The observed complex alterations in the FA signatures could have both contributed to but also limited
the inflammatory processes and cartilage destruction in the RA and OA knees.
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The potential inflammatory role of the infrapatellar fat
pad (IFP) has recently become a topic of interest for
osteoarthritis (OA) [1] and rheumatoid arthritis (RA) re-
search [2]. IFP is an intracapsular but extrasynovial organ
that does not directly interact with the articular cartilage
[3]. It has, however, been proposed to be a source of fatty© The Author(s). 2019 Open Access This artic
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tokines that could contribute to the pathophysiological
processes in knee arthropathies [1, 2, 4]. IFP-conditioned
medium is able to stimulate OA fibroblast-like synovio-
cytes to produce prostaglandin E2 (PGE2), cytokines, and
cartilage-degrading enzymes [5], which suggests a role as
an anatomical site in the complex process of knee joint in-
flammation. RA synovial tissues typically have a more in-
flammatory phenotype with more infiltrating immune
cells and a higher expression of cytokines than OA joints
[6]. The IFP of RA patients is also infiltrated by a higher
number of immune cells, while the types and levels of se-
creted adipocytokines are similar to OA [2].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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produced ultrafiltrate of blood plasma that contains lubri-
cating compounds, such as hyaluronan and phospholipids
(PL). The concentrations of cholesterol, lipoproteins, and
apolipoproteins increase in RA SF [7]. In addition, the
levels of various glycero-PL and sphingolipids are elevated
in RA and OA SF [8, 9]. FA and their derivatives have
been proposed to play roles in the pathophysiology of
joint diseases [10]. Changes in the desaturation and chain
length of FA could affect the anti-friction and lubricating
properties of surface-active PL that cover the articular car-
tilage [11, 12]. Local FA concentrations could also contrib-
ute to inflammatory processes and cartilage degradation
[10]. Generally, n-6 polyunsaturated FA (PUFA), which
are overrepresented in the Western diet [13, 14], are pre-
cursors to pro-inflammatory LM, while n-3 PUFA are
converted to less inflammatory or resolving ones [10, 15].
In fact, n-3 PUFA, especially 20:5n-3 (eicosapentaenoic
acid), have anti-inflammatory and anti-destructive effects
on cartilage [16, 17]. In agreement with this, dietary fish
oil supplements containing high proportions of 20:5n-3
and 22:6n-3 (docosahexaenoic acid) can reduce the tender
joint count and morning stiffness in RA patients [18]. In-
creased consumption of long-chain n-3 PUFA may also
have beneficial effects on pain alleviation and function of
OA joints, although the evidence is less convincing [19].
The major dietary n-6 PUFA, 18:2n-6 (linoleic acid),
when first converted to 20:4n-6 (arachidonic acid), can
have pro-inflammatory effects on cartilage via increased
PGE2 production [20]. OA joints have been documented
to accumulate n-6 PUFA, especially 20:4n-6, the imme-
diate precursor of PGE2 [21, 22]. The major monoun-
saturated FA (MUFA), 18:1n-9 (oleic acid), inhibits
cartilage destruction, while the role for the most com-
mon saturated FA (SFA), 16:0 (palmitic acid), remains
controversial [20, 23]. According to Lu et al. [24], a high
dietary intake of SFA can be associated with the progres-
sion of knee OA, while dietary PUFA and MUFA have
potentially protective effects. PGE2 levels can be elevated
in SF/plasma of RA and OA patients [10]. However,
pro-resolving LM can be also detected in both RA and
OA joints, where they could potentially contribute to
the resolution pathways [25–27].
Previous studies focusing on the detailed assessment
of FA signatures in RA or OA joints are scarce. To
assess the contribution of IFP to knee arthropathies,
our aim was to examine the proportions of a compre-
hensive array of FA in the IFP and SF of RA and OA
patients. To the best of our knowledge, this is the
first time the FA profiles of IFP and SF sample pairs
from the same knees are compared between RA and
OA. It was hypothesized that RA would be character-
ized with a more pro-inflammatory FA signature
compared to OA in both IFP and SF.Methods
Subjects, ethics, and sampling
Patients with knee joint disorders (seropositive RA: men
n = 3, women n = 7; primary OA: men n = 2, women n = 8;
Table 1) were recruited at the Oulu University Hospital
with the permission of the Ethical Committee of the Hos-
pital (decision #29/2011, amendment 2/24/2014) in com-
pliance with the Helsinki Declaration. As the selection
criteria, we only sampled patients who had reached the
age of majority (18 years) and were undergoing knee sur-
gery for pre-existing medical indications (Table 2). Prior
to the surgery, all patients signed consent forms to donate
their IFP and SF samples. General data were recorded as
follows: sex, age, body mass, height, body mass index
(BMI), operation, operative diagnosis, and medication. No
data that would enable the identification of the patients
were registered.
SF samples were collected with sterile needles and syrin-
ges during joint replacement surgery performed at the
Oulu University Hospital in 2011–2017 and stored at
− 70 °C. IFP samples were harvested from the same pa-
tients during the removal of periarticular tissues according
to the demands of the joint replacement procedure. All
samples were obtained during surgery for pre-existing in-
dications, and they represented tissues that would have
been removed during surgery regardless of the study. The
total duration of the surgery increased only by a minimal
amount of time due to sampling. For comparison, control
SF samples (men n = 2, women n = 4) were collected dur-
ing arthroscopic knee surgery performed as diagnostic
arthroscopy or due to trauma without underlying RA/OA
at the Kuopio University Hospital in 2014 with the per-
mission of the Ethical Committee of the Hospital (decision
#79//2013) in compliance with the Helsinki Declaration.
The samples were stored at − 80 °C. The selection criteria
for control patients and the collection of general data were
similar to patients with RA and OA.
FA analyses
Subsamples of IFP and SF were transmethylated in metha-
nolic H2SO4 under nitrogen atmosphere [28], and the
formed FA methyl esters (FAME) were extracted with
hexane and analyzed by a Shimadzu GC-2010 Plus gas
chromatograph (Shimadzu, Kyoto, Japan) employing flame
ionization detector (FID). The FAME structures were con-
firmed by using electron impact mass spectra recorded by
a Shimadzu GCMS-QP2010 Ultra with a mass selective
detector. The resulting chromatographic peaks from FID
were manually integrated with the GCsolution software
(v2.41.00) by Shimadzu. The results represent the FA
composition (mol-%) of IFP and SF total lipids, and when
calculating indices, as defined below, the mol-% values of
the FA were always used. The n-6 and n-3 PUFA product/
precursor ratios were calculated as follows: (20:3n-6 +
Table 1 Demographic characteristics of the sampled knee surgery patients (mean ± SEM)
Group Control RA OA p group p sex p interaction
Sex 2 M, 4 F 3 M, 7 F 2 M, 8 F 0.869
Age (years) 34 ± 4 72 ± 3* 66 ± 3* < 1 × 10−15 0.935 0.005
Body mass (kg) 76.3 ± 7.19 67.2 ± 5.97 82.6 ± 4.53 0.622 0.666 0.064
BMI (kg/m2) 26.0 ± 2.26 24.9 ± 1.50 31.2 ± 1.76 0.326 0.062 0.021
Sex ratios were tested with the Fisherʼs exact test
RA rheumatoid arthritis, OA osteoarthritis, M male, F female, BMI body mass index
*Significant difference from control (generalized linear model)
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double bond index (DBI) was calculated by using the for-
mula: [(1 × (Σ MUFA)) + (2 × (Σ dienoic FA)) + (3 × (Σ tri-
enoic FA)) + (4 × (Σ tetraenoic FA)) + (5 × (Σ pentaenoic
FA)) + (6 × (Σ hexaenoic FA))]/100. The total average
chain length (TACL) was calculated as follows: [(14 × (Σ
14C FA)) + (15 × (Σ 15C FA)) + (16 × (Σ 16C FA))
+ (17 × (Σ 17C FA)) + (18 × (Σ 18C FA)) + (19 × (Σ 19CTable 2 Clinical characteristics and diagnoses of the sampled knee
ID Group Gender Operation
01 Control M Arthroscop
02 Control F Arthroscop
03 Control F Arthroscop
04 Control F Diagnostic
05 Control F Arthroscop
06 Control M Arthroscop
07 RA F Total knee
08 RA F Total knee
09 RA F Total knee
10 RA F Total knee
11 RA M Total knee
12 RA F Total knee
13 RA F Total knee
14 RA M Total knee
15 RA M Total knee
16 RA F Total knee
17 OA M Total knee
18 OA M Total knee
19 OA F Total knee
20 OA F Total knee
21 OA F Total knee
22 OA F Total knee
23 OA F Total knee
24 OA F Total knee
25 OA F Total knee
26 OA F Total knee
M male, F female, RA rheumatoid arthritis, OA osteoarthritis, MPFL medial patellofem
M22.0 recurrent dislocation of patella, M23.5 chronic instability of the knee, M23.2 d
other secondary gonarthrosis, M17.4 other secondary gonarthrosis, bilateral, M17.1 oFA)) + (20 × (Σ 20C FA)) + (22 × (Σ 22C FA)) + (24 × (Σ
24C FA))]/100. The Δ9-desaturation index was calculated
with the formula: [(14:1n-5 + 16:1n-9 + 16:1n-7 + 16:1n-5
+ 17:1n-8 + 18:1n-9 + 18:1n-7 + 18:1n-5 + 20:1n-11 + 20:1n-9
+ 20:1n-7 + 22:1n-11 + 22:1n-9 + 22:1n-7 + 24:1n-9)/(14:0
+ 16:0 + 17:0 + 18:0 + 20:0 + 22:0 + 24:0)], which included
all the MUFA irrespective of whether their production
also required chain-elongation or chain-shortening stepssurgery patients
Operative diagnosis
y, MPFL reconstruction M22.0
y, MPFL reconstruction M22.0
y, ACL reconstruction M23.5, M23.2
arthroscopy M23.5
y, debridement M25.5






replacement M17.4 (other secondary)
replacement M17.4 (other secondary)
replacement M17.5 (secondary)
replacement M17.5 (secondary)











oral ligament, ACL anterior cruciate ligament, med. men. medial meniscus,
erangement of meniscus due to old tear or injury, M25.5 pain in joint, M17.5
ther primary gonarthrosis
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saturation index was calculated as 18:3n-6/18:2n-6 (since
18:4n-3 did not accumulate in the studied tissues, 18:4n-3/
18:3n-3 ratio was not used) and the Δ5-desaturation index
as 20:4n-6/20:3n-6 and 20:5n-3/20:4n-3.Statistical analyses
Comparisons between the study groups were performed
with the generalized linear model executed with the nor-
mal probability distribution (IBM SPSS v25 software,
IBM, Armonk, NY, USA). The examined parameter was
the dependent variable and the study group the model
factor. Relative differences in the FA proportions be-
tween IFP and SF were tested with the independent
samples t test. Sex ratios in the study groups were tested
with Fisherʼs exact test. Correlations were calculated
with the Spearman correlation coefficient (rs). The p
value < 0.05 was considered statistically significant. The
results are presented as the mean ± standard error of the
mean (SEM). To carry out a general assessment of the
FA profiles, we also performed the discriminant ana-
lysis by classifying FA data by discriminant functions
to determine how the samples in the study groups
differed from one another, which variables separated
them most clearly, and how well the analysis was ableFig. 1 Discriminant analysis depicting the classification of fatty acid signatu
With these first two functions, 98.4% of the variance was explained. IFP infr
arthritis. Note that the scaling is different in the x- and y-axesto classify the samples into their respective study
groups: control, RA, or OA.
Results
General demographic data of the patients are presented
in Table 1. The RA and OA patients were significantly
older than those in the control group. The body masses
or BMI were not affected by the diagnoses. Neither did
sex have an effect on the general characteristics of the
patients, but there was a significant group × sex inter-
action regarding age and BMI.
In the discriminant analysis, the five study groups were
clearly separated from each other based on the FA signa-
tures (Fig. 1). The FA having the largest separation
power included 18:2n-6, 22:4n-6, 18:3n-3, 22:6n-3,
18:1n-9, and 20:4n-6. The analysis classified 100% of the
samples correctly into their respective study groups. The
general differences in the FA profiles between IFP and
SF can be examined in Table 3.
According to the generalized linear model, RA SF had
higher proportions of 16:1n-5, 17:0ai, DMA 18:1n-7 (di-
methyl acetal), and total MUFA compared to control SF,
while 18:2n-6, 24:0, and TACL were lower (Table 3). Re-
garding OA SF, the proportions of 14:1n-5, 15:0, DMA
18:1n-7, 18:1n-9, and total MUFA were elevated and
those of 18:2n-6, 20:4n-6, 24:0, 22:6n-3, total PUFA, andres in the studied tissues based on discriminant functions 1 and 2.
apatellar fat pad, SF synovial fluid, OA osteoarthritis, RA rheumatoid
Table 3 Percentages (mol-%) of individual fatty acids (FA), sums of different FA classes, ratios, and indices in synovial fluid (SF) and
infrapatellar fat pad (IFP; mean ± SEM)
Control SF RA SF OA SF RA IFP OA IFP p
14:0 3.310 ± 0.272 3.778 ± 0.154 3.801 ± 0.217 3.733 ± 0.195 3.174 ± 0.150‡, # 0.033
14:1n-5 0.224 ± 0.035 0.342 ± 0.045 0.330 ± 0.026* 0.617 ± 0.073# 0.495 ± 0.065# 0.000001
15:0 0.230 ± 0.013 0.264 ± 0.020 0.285 ± 0.014* 0.344 ± 0.024# 0.313 ± 0.020 0.001
DMA 16:0 0.096 ± 0.018 0.091 ± 0.008 0.092 ± 0.007 0.016 ± 0.005# 0.037 ± 0.012# 3.1 × 10−14
16:0 28.222 ± 0.772 28.823 ± 0.417 29.301 ± 0.727 23.216 ± 1.205# 24.604 ± 0.644# 5.5 × 10−11
16:1n-9 0.400 ± 0.032 0.416 ± 0.015 0.374 ± 0.023 0.626 ± 0.039# 0.741 ± 0.050# < 10−20
16:1n-7 2.011 ± 0.130 2.725 ± 0.351 2.867 ± 0.414 7.670 ± 0.821# 6.732 ± 0.789# 3.3 × 10−16
16:1n-5 0.217 ± 0.029 0.327 ± 0.031* 0.232 ± 0.025† 0.170 ± 0.019# 0.195 ± 0.034 0.000222
17:0i 0.106 ± 0.005 0.112 ± 0.018 0.119 ± 0.015 0.064 ± 0.005# 0.063 ± 0.010# 0.000254
17:0ai 0.251 ± 0.028 0.330 ± 0.026* 0.304 ± 0.023 0.213 ± 0.011# 0.215 ± 0.023# 0.000022
17:0 0.587 ± 0.053 0.531 ± 0.029 0.589 ± 0.050 0.211 ± 0.033# 0.263 ± 0.040# < 10−20
17:1n-8 0.157 ± 0.025 0.196 ± 0.014 0.188 ± 0.023 0.297 ± 0.014# 0.299 ± 0.022# 6.0 × 10−10
DMA 18:0 0.347 ± 0.032 0.374 ± 0.024 0.316 ± 0.036 0.041 ± 0.018# 0.078 ± 0.022# < 10−20
DMA 18:1n-9 0.301 ± 0.047 0.353 ± 0.046 0.329 ± 0.041 0.031 ± 0.016# 0.081 ± 0.034# 1.9 × 10−15
DMA 18:1n-7 0.029 ± 0.004 0.059 ± 0.007* 0.065 ± 0.009* 0.010 ± 0.005# 0.025 ± 0.009# 1.4 × 10−9
18:0 13.640 ± 0.843 14.077 ± 0.729 15.041 ± 1.159 3.784 ± 0.673# 5.137 ± 0.848# < 10−20
18:1n-9 22.996 ± 1.009 25.107 ± 0.764 26.424 ± 1.225* 44.581 ± 1.198# 40.945 ± 1.738# < 10−20
18:1n-7 2.700 ± 0.138 3.006 ± 0.049 3.010 ± 0.108 2.989 ± 0.167 3.262 ± 0.193 0.124
18:1n-5 0.668 ± 0.056 0.834 ± 0.079 0.718 ± 0.073 0.181 ± 0.056# 0.201 ± 0.052# < 10−20
18:2n-7 0.278 ± 0.036 0.229 ± 0.030 0.243 ± 0.022 0.212 ± 0.023 0.180 ± 0.016 0.087
18:2n-6 14.460 ± 2.395 10.205 ± 0.983* 8.291 ± 1.056* 7.198 ± 0.231# 8.068 ± 0.473 0.00001
18:3n-6 0.066 ± 0.023 0.112 ± 0.046 0.123 ± 0.062 0.031 ± 0.011 0.047 ± 0.008 0.276
19:1n-8 0.077 ± 0.020 0.073 ± 0.010 0.098 ± 0.018 0.077 ± 0.009 0.063 ± 0.007 0.323
18:3n-3 0.592 ± 0.063 0.659 ± 0.045 0.610 ± 0.031 0.846 ± 0.041# 0.773 ± 0.074# 0.001
18:2c9t11 0.093 ± 0.031 0.082 ± 0.011 0.105 ± 0.043 0.179 ± 0.064# 0.292 ± 0.097# 0.049
20:0 0.294 ± 0.034 0.244 ± 0.009 0.266 ± 0.029 0.086 ± 0.012# 0.087 ± 0.020# < 10−20
20:1n-11 0.156 ± 0.042 0.120 ± 0.016 0.212 ± 0.057 0.191 ± 0.022 0.193 ± 0.038 0.358
20:1n-9 0.336 ± 0.162 0.207 ± 0.026 0.229 ± 0.042 0.569 ± 0.028# 0.411 ± 0.031‡, # 6.3 × 10−7
20:1n-7 0.130 ± 0.048 0.107 ± 0.012 0.166 ± 0.086 0.087 ± 0.007 0.092 ± 0.007 0.644
20:2n-9 0.176 ± 0.107 0.101 ± 0.016 0.073 ± 0.005 0.041 ± 0.012# 0.057 ± 0.009 0.048
20:2n-6 0.229 ± 0.035 0.193 ± 0.023 0.190 ± 0.043 0.116 ± 0.038 0.281 ± 0.077 0.128
20:3n-9 0.039 ± 0.007 0.042 ± 0.007 0.044 ± 0.011 0.014 ± 0.004# 0.019 ± 0.004# 0.002
20:3n-6 0.743 ± 0.137 0.676 ± 0.056 0.586 ± 0.070 0.139 ± 0.021# 0.171 ± 0.027# < 10−20
20:4n-6 3.159 ± 0.594 2.470 ± 0.227 1.790 ± 0.269*, † 0.337 ± 0.097# 0.742 ± 0.176‡, # < 10−20
20:4n-3 0.619 ± 0.057 0.741 ± 0.075 0.769 ± 0.130 0.122 ± 0.043# 0.192 ± 0.052# 7.6 × 10−14
20:5n-3 0.419 ± 0.087 0.355 ± 0.067 0.289 ± 0.048 0.069 ± 0.011# 0.092 ± 0.014# 2.9 × 10−9
22:0 0.205 ± 0.022 0.268 ± 0.057 0.311 ± 0.054 0.083 ± 0.043# 0.177 ± 0.068 0.016
22:1n-11 0.040 ± 0.006 0.046 ± 0.006 0.045 ± 0.005 0.025 ± 0.007# 0.024 ± 0.005# 0.002
22:1n-9 0.129 ± 0.008 0.131 ± 0.016 0.121 ± 0.012 0.057 ± 0.013# 0.063 ± 0.014# 8.9 × 10−7
22:1n-7 0.028 ± 0.005 0.025 ± 0.003 0.035 ± 0.006 0.010 ± 0.004# 0.010 ± 0.003# 0.000002
22:4n-6 0.041 ± 0.010 0.033 ± 0.004 0.125 ± 0.064 0.105 ± 0.018# 0.227 ± 0.038‡, # 0.001
22:5n-3 0.078 ± 0.014 0.128 ± 0.028 0.172 ± 0.042 0.350 ± 0.138 0.366 ± 0.054# 0.014
24:0 0.388 ± 0.020 0.331 ± 0.018* 0.282 ± 0.025* 0.044 ± 0.024# 0.068 ± 0.018# < 10−20
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Table 3 Percentages (mol-%) of individual fatty acids (FA), sums of different FA classes, ratios, and indices in synovial fluid (SF) and
infrapatellar fat pad (IFP; mean ± SEM) (Continued)
Control SF RA SF OA SF RA IFP OA IFP p
22:6n-3 0.626 ± 0.097 0.556 ± 0.065 0.327 ± 0.059*, † 0.191 ± 0.036# 0.396 ± 0.040‡ 8.6 × 10−8
24:1n-9 0.107 ± 0.017 0.122 ± 0.015 0.108 ± 0.018 0.029 ± 0.008# 0.048 ± 0.008# 1.2 × 10−8
SFA 47.232 ± 1.936 48.758 ± 1.287 50.301 ± 2.024 31.778 ± 1.781# 34.102 ± 1.471# < 10−20
MUFA 30.377 ± 1.306 33.783 ± 1.100* 35.159 ± 1.638* 58.174 ± 1.891# 53.774 ± 1.825# < 10−20
PUFA 21.618 ± 3.251 16.581 ± 1.251 13.739 ± 1.263* 9.950 ± 0.488# 11.902 ± 0.574‡ 6.8 × 10−9
n-6 PUFA 18.699 ± 3.102 13.689 ± 1.201 11.106 ± 1.267* 7.927 ± 0.260# 9.536 ± 0.466‡ 2.6 × 10−8
n-3 PUFA 2.334 ± 0.182 2.439 ± 0.135 2.167 ± 0.178 1.578 ± 0.225# 1.819 ± 0.114 0.000484
n-9 PUFA 0.215 ± 0.106 0.143 ± 0.014 0.117 ± 0.013 0.055 ± 0.016# 0.075 ± 0.010# 0.009
DMA 0.773 ± 0.078 0.877 ± 0.069 0.801 ± 0.079 0.098 ± 0.042# 0.221 ± 0.076# < 10−20
UFA/SFA 1.118 ± 0.082 1.046 ± 0.056 1.004 ± 0.089 2.247 ± 0.207# 1.971 ± 0.117# < 10−20
n-3/n-6 PUFA 0.148 ± 0.029 0.192 ± 0.021 0.220 ± 0.035 0.197 ± 0.022 0.191 ± 0.009 0.393
Prod/prec n-6 PUFA 0.267 ± 0.012 0.313 ± 0.014 0.300 ± 0.036 0.068 ± 0.017# 0.122 ± 0.032# < 10−20
Prod/prec n-3 PUFA 1.834 ± 0.355 1.408 ± 0.160 1.023 ± 0.135* 0.320 ± 0.062# 0.692 ± 0.099‡, # 5.5 × 10−12
TACL 17.26 ± 0.06 17.16 ± 0.02* 17.14 ± 0.03* 17.18 ± 0.03 17.20 ± 0.03 0.044
DBI 0.87 ± 0.07 0.79 ± 0.03 0.72 ± 0.04* 0.82 ± 0.02 0.84 ± 0.01# 0.010
Δ9-DI 0.65 ± 0.01 0.71 ± 0.04 0.73 ± 0.07 1.96 ± 0.19# 1.64 ± 0.11# < 10−20
Δ6-DI n-6 PUFA 0.005 ± < 0.01 0.02 ± 0.01 0.02 ± 0.02 0.004 ± < 0.01 0.006 ± < 0.01 0.323
Δ5-DI n-6 PUFA 4.28 ± 0.60 3.68 ± 0.23 3.07 ± 0.32 2.22 ± 0.25 5.38 ± 1.67 0.058
Δ5-DI n-3 PUFA 0.75 ± 0.20 0.53 ± 0.09 0.42 ± 0.08 0.76 ± 0.11 0.66 ± 0.12 0.134
RA rheumatoid arthritis, OA osteoarthritis, DMA dimethyl acetal, i.e. plasmalogen alkenyl chain derivative, i iso, ai anteiso, c cis, t trans, SFA saturated fatty acid,
MUFA monounsaturated fatty acid, PUFA polyunsaturated fatty acid, UFA unsaturated fatty acid (MUFA + PUFA), prod product, prec precursor, TACL total average
chain length, DBI double bond index, Δ9-DI Δ9-desaturation index, Δ6-DI Δ6-desaturation index, Δ5-DI Δ5-desaturation index
*Significant difference from the control SF
†Significant difference between RA and OA SF
‡Significant difference between RA and OA IFP
#Significant difference between IFP and SF within a diagnosis (generalized linear model)
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tios of n-3 PUFA, TACL, and DBI decreased compared
to control SF. RA SF had higher percentages of 16:1n-5,
20:4n-6, and 22:6n-3 than OA SF. Regarding IFP, RA
lipids had higher proportions of 14:0 and 20:1n-9 but
lower percentages of 20:4n-6, 22:4n-6, 22:6n-3, total
PUFA, and n-6 PUFA, and decreased product/precursor
ratios of n-3 PUFA.
The n-3/n-6 PUFA ratios of SF correlated positively
with the n-3/n-6 PUFA ratios of IFP in RA patients (rs =
0.903, p < 0.0004) but not in OA patients (rs = 0.200, p =
0.580). Similarly, the n-3 PUFA sums correlated posi-
tively between SF and IFP in RA patients (rs = 0.709, p =
0.022) but not in OA patients (rs = 0.321, p = 0.365), and
the 18:1n-9 proportions between SF and IFP in OA pa-
tients (rs = 0.648, p = 0.043) but not in RA patients (rs =
− 0.321, p = 0.365). In addition, the BMI correlated in-
versely with the SF proportions of 22:6n-3 in RA pa-
tients (rs = − 0.723, p = 0.018) but not in OA patients (rs
= − 0.406, p = 0.244). There were no significant correla-
tions between the BMI and n-3 or n-6 PUFA sums, nor
the n-3/n-6 PUFA ratios in SF or IFP (rs = − 0.479–
0.200, p = 0.162–0.947) except for the n-6 PUFA sums inthe IFP of RA group (rs = − 0.729, p = 0.017). In the gen-
eralized linear model with BMI as a covariate, the effects
of the BMI on the SF and IFP n-3 PUFA sums, n-6
PUFA sums, and n-3/n-6 PUFA ratios were nonsignifi-
cant (p = 0.266–0.566).
Discussion
The significance of age, sex, and obesity in joint disor-
ders is well-documented, which was also confirmed in
the discriminant analysis of the present study. However,
the novelty of our results is in the FA part of the study
and in the potential dialogue between the FA profiles
and inflammatory phenomena in the two major joint
diseases, RA and OA. The main findings of the present
study were as follows: (i) n-6 PUFA reduced in propor-
tion in RA SF and especially in OA SF compared to con-
trol knees, (ii) 22:6n-3 and product/precursor ratios of
n-3 PUFA decreased in OA SF, (iii) TACL and DBI re-
duced especially in OA SF, and (iv) total n-6 PUFA,
20:4n-6, 22:6n-3, and product/precursor ratios of n-3
PUFA were lower in RA IFP than in OA IFP.
It was initially hypothesized that the RA knee would
exhibit a more pro-inflammatory FA signature compared
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PUFA in the SF of both RA and OA patients, as well as
lower 20:4n-6 and total n-6 PUFA proportions in RA
IFP compared to OA IFP. There is a growing consensus
for a detrimental role of n-6 PUFA and their derivatives
in joint health. It has been established that n-6 PUFA,
especially 20:4n-6, can accumulate in OA joints [21, 22]
and that they increase cyclooxygenase-2 protein levels
[29] and PGE2 production in chondrocytes [20]. In
plasma PL, 20:4n-6 levels were positively associated with
the degree of knee synovitis [30], and low dietary
20:4n-6 intake reduced inflammation in RA patients
[31]. In addition, the secretion of 20:4n-6 was higher
from the IFP of OA patients compared to post-mortem
donors without OA [4]. However, the situation is more
complex, as n-6 PUFA also have potential roles in the
pathways of resolution of inflammation [32]. Previously,
18:3n-6 (gamma-linolenic acid) was noted to improve
signs and symptoms of RA disease activity [33], and in a
recent study, 18:2n-6 levels in erythrocytes were in-
versely associated with the risk of RA [34]. According to
Van de Vyver et al. [35], 20:4n-6 concentrations de-
creased in the SF free FA of patients with end-stage knee
OA, supporting the present results.
To the best of our knowledge, the observed reduction in
the proportions of n-6 PUFA has not been previously docu-
mented for RA SF or IFP, but some similarities have been
reported for the circulating levels of n-6 PUFA in RA pa-
tients [36–38]. It is tempting to hypothesize that the de-
creased relative proportions of n-6 PUFA in SF could
reduce inflammation and, in this way, provide a potentially
protective mechanism in knee arthropathies. Alternatively,
the reduced SF proportions of 18:2n-6 and 20:4n-6 could
have been due to their intensified conversion to short-lived
LM. This view is supported by the SF activity of phospho-
lipase A2 [39], an enzyme that cleaves PUFA from PL for
LM synthesis. In addition, based on the few liquid chroma-
tography–tandem mass spectrometry studies conducted, SF
contains several pro- and anti-inflammatory LM originating
from n-6 and n-3 PUFA [25, 40].
In addition to the loss of n-6 PUFA, we documented
reduced 22:6n-3 proportions in OA SF, also reflected in
the decreased n-3 PUFA product/precursor ratios. Previ-
ous data have shown that n-3 PUFA can have protective
effects on joint tissues, for instance, by reducing the pro-
duction of cyclooxygenase-2, inflammatory cytokines,
and cartilage-degrading enzymes [16, 17, 29] and, for
these reasons, the relative decrease of 22:6n-3 in the OA
SF samples was expected. Earlier, the mobilization of
22:6n-3 from IFP was higher in OA patients than in
post-mortem donors without OA [4]. As 22:6n-3 is a
precursor of pro-resolving LM, it could contribute to
the resolution pathways in diseased joints [25–27]. The
n-3 PUFA levels in the SF of RA patients of the presentstudy were not different from controls, and their 22:6n-3
percentages were somewhat higher than in OA SF. This
is opposite to the findings of Navarro et al. [37], who
documented decreased n-3 PUFA levels in the SF of RA
patients compared to those with OA. These data agree
with the literature in which a higher dietary intake of
long-chain n-3 PUFA has been associated with a lower
risk of developing RA [41] and in which dietary fish oil
supplements have reduced tender joint count and stiff-
ness of RA joints [18]. In contrast to our SF results, the
lower 22:6n-3 proportions in RA IFP compared to OA
IFP would be in line with earlier literature.
A high n-6/n-3 PUFA ratio in the diet and in the body
is associated with obesity and several other pathological
conditions [13, 14]. Our research group observed an in-
crease in the IFP n-6/n-3 PUFA ratio due to experimen-
tally induced early OA in a rabbit model [42] and, in
human plasma, a high n-6/n-3 PUFA ratio was associ-
ated with greater pain and functional limitations of the
OA knee [43], suggesting implications in joint diseases.
However, there was no relationship between SF n-3/n-6
PUFA ratios and OA severity or synovitis in an obese
mouse model of OA [44]. In the present study, the n-3/
n-6 PUFA ratios in SF and IFP were unaffected by RA or
OA, which could mean that both types of PUFA are
used for LM production, also supported by the previous
liquid chromatography–tandem mass spectrometry pro-
filing studies of SF LM [25, 27, 40]. We did not find in-
creased product/precursor ratios of n-6 PUFA, different
from previous literature on serum PL [36, 38]. Neither
were there statistically significant differences in the Δ6-
or Δ5-desaturation indices according to the diagnoses.
These results are in line with the study by de Pablo et al.
[34], who found no significant association between these
indicators of PUFA metabolism and the risk of RA.
The present results also revealed an increase in the SF
proportions of total MUFA in both RA and OA. Previ-
ously, Navarro et al. [37] documented elevated percent-
ages of long-chain MUFA in RA SF, possibly in
association with increased sphingomyelin levels. In the
present study, 18:1n-9 showed increased percentages in
OA SF and, previously, it was identified as a critical me-
tabolite for discriminating between early- and late-stage
OA with increased levels in SF during disease progres-
sion [45]. The possible role for MUFA in joint diseases
is not clear, but 18:1n-9 has exerted anti-destructive ef-
fects on chondrocytes and cartilage in vitro [20]. In this
way, the elevated MUFA proportions could counteract
pathologic processes in RA and OA.
A high dietary intake of SFA was previously connected
to the disease progression of knee OA [24] and the
major SFA, 16:0, induced inflammation, articular cartil-
age breakdown, and chondrocyte apoptosis in vitro [23].
However, 16:0 was also documented to inhibit cartilage
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model of OA reported negative association of SF SFA
with OA severity [44]. We did not find significant
changes in the proportions of major SFA between RA
and OA SF or IFP, while Navarro et al. [37] observed in-
creased 16:0 and total SFA levels in the SF of RA com-
pared to OA patients. To sum up the present results,
the major differences between the control knees and the
RA and OA joints were an increase in MUFA and a simul-
taneous decrease in n-6 PUFA. It has been previously pro-
posed that IFP could inhibit catabolic processes in the
end-stage OA [46]. Together, these findings suggest that
in addition to destructive cascades in the diseased joint,
protective biochemical phenomena may also arise, when a
share of n-6 PUFA is replaced with MUFA, perhaps fol-
lowing intense consumption of n-6 PUFA precursors for
LM production. These observations have potential trans-
lational applications, as altering the FA profile could help
alleviate the pathological processes in both RA and OA.
Even though PL levels in SF have been documented to
be elevated in RA and OA [8, 9], articular surfaces have
been proposed to become deficient in surface-active PL in
OA [47]. Changes in the desaturation and length of FA
chains could influence the anti-friction and lubricating
properties of these PL covering the articular cartilage [11,
12]. Kosinska et al. [12] suggested that there could be an
increase in the PL species with longer FA chains in RA
and OA, which could hypothetically reduce friction and
protect articular surfaces. We found decreased TACL in
both RA and OA SF and reduced DBI in OA SF. Provided
that PL with longer-chain and more unsaturated FA wouldFig. 2 The relative differences (%) in the proportions of selected fatty acids
osteoarthritis, RA rheumatoid arthritis. The bars with negative values indica
with positive values indicate higher percentages in SF than in IFP [(mol-%
significant difference between OA and RA (t test, p < 0.05)reduce the coefficient of friction in joints [48], the de-
creased TACL and DBI could be examples of harmful FA
alterations in RA and OA, in contrast to the observed de-
crease in n-6 PUFA and the increase in MUFA.
It has been proposed that most SF FA would derive
from plasma [37], but IFP has also been suggested to be
one source of FA and LM affecting the knee joint [4, 5,
49]. IFP has been assumed to induce both protective and
disease-aggravating activities in the OA knee [49]. The
interrelations between the IFP and SF FA profiles were
assessed here by the simultaneous analysis of these tis-
sues from the same knees, and the relative differences in
the proportions of FA between IFP and SF are repre-
sented in Fig. 2. The proportions of several long-chain
SFA and MUFA were higher in SF, and their source
could possibly be plasma sphingomyelin known to har-
bor these FA [50]. We only found a few significant cor-
relations in the FA proportions between IFP and SF.
This could indicate that the release of FA from IFP may
not be as prominent as could be assumed or that it is
mostly the FA-derived LM that are released from IFP to
SF via the synovial membrane. SF lipids may also derive
directly from tissue destruction in diseased joints caus-
ing the IFP and SF FA profiles to diverge.
When investigating the reasons behind the tissue- and
diagnosis-specific differences in the FA composition, the
relative importance of the changes due to systemic PUFA
distribution in the body vs. locally different PUFA metabol-
ism is difficult to address. However, no tissues of any wild
type mammals are able to convert n-6 PUFA to n-3 PUFA
or vice versa, a trait only possible through introduced genes(FA) between tissues. IFP infrapatellar fat pad, SF synovial fluid, OA
te that a FA had higher percentages in IFP than in SF, and the bars
in SF–mol-% in IFP)/mol-% in IFP; mean + SEM]. Asterisk denotes
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PUFA families affect each other’s metabolism by compet-
ing for the same enzymatic conversions, especially for the
further Δ6- and Δ5-desaturations of PUFA precursors that
already have the n-3 or n-6 double bond in place [52].
However, this competition that can be found in the struc-
tural modifications of PUFA does not seem to occur be-
tween n-3 and n-6 PUFA in the cycles of incorporation
and hydrolysis that remodel the lipid acyl chains [53]. In
addition, different phospholipases have preferred sub-
strates, and the hydrolysis rates depend on the lipid mol-
ecule head group and acyl chains [54]. Thus, specific
PUFA may be hydrolyzed and consumed at different rates
when cyclooxygenase, lipoxygenase, and cytochrome P450
monooxygenase enzymes convert n-6 and n-3 PUFA to
various LM [55, 56].
Some potential limitations regarding the present study
should be acknowledged. The control group for SF was
relatively small and, in addition, the IFP samples unfortu-
nately lacked a control group. This was due to ethical rea-
sons, as IFP is not routinely removed during arthroscopic
surgery unlike in total joint replacement. Furthermore, the
control SF samples do not represent healthy but RA- and
OA-free joints, and knee trauma can influence the SF lipid
composition [57]. In addition, the control patients were sig-
nificantly younger than the RA and OA groups, which is
quite unavoidable considering the demographics of degen-
erative joint diseases vs. knee trauma. The effects of age on
body FA profiles cannot be excluded [58]. While this vari-
able may be a confounding factor regarding the study
population, it would be logistically difficult to obtain an
age-standardized sample population regarding knee dis-
eases. By the time of the knee replacement surgery, the pa-
tients had a long disease history that had been treated with
systemic and local medications, and we cannot exclude the
possibility that some of these could have influenced the FA
profiles, especially regarding the usually more intensively
medicated RA patients.
Conclusions
The FA signatures in IFP and SF were clearly different be-
tween the studied diagnoses. These changes could contrib-
ute to disease progression by influencing inflammatory
processes, cartilage destruction, and friction in the joint.
The FA manifestations of RA and OA could not be
regarded as strictly pro-inflammatory or ameliorating but
likely reflected both inflammation and protective biochem-
ical phenomena. The major changes from the control knees
to the RA and OA joints were an increase in MUFA and a
simultaneous decrease in n-6 PUFA. There is accumulating
evidence for a protective role of n-3 PUFA in joint health,
but the potential roles of the n-6 PUFA loss and the in-
crease in MUFA should be investigated in future studies on
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